Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes.
BACKGROUND
Enteroviral ribonucleic acids have been identified in heart muscle of a subset of patients with myocarditis and dilated cardiomyopathy as well as in a mouse model of persistent coxsackievirus B3 (CVB3) infection, suggesting that persistent viral infection along with activation of an immune response may contribute to the pathogenesis of ongoing cardiac disease and dilated cardiomyopathy in certain patients. It is still not known whether persistence of the viral genome contributes to the pathogenesis of dilated cardiomyopathy.


RESULTS
To determine whether low-level enteroviral gene expression similar to that observed with viral persistence can induce myocytopathic effects without formation of infectious virus progeny, the full-length infectious cDNA copy of CVB3 was mutated at the VP0 maturation cleavage site. This prevented formation of infectious virus progeny. In myocytes transfected with this mutated cDNA copy of the viral genome, both positive- and negative-strand viral RNAs were detected, demonstrating that there was replication of the viral genome by the RNA-dependent RNA polymerase. The level of viral protein expression was found to be below limits of detection by conventional methods of protein detection, thus resembling restricted virus replication. Nonetheless, the CVB3 mutant was found to induce a cytopathic effect in transfected myocytes, which was demonstrated by inhibition of cotransfected MLC-2v luciferase reporter activity and an increase in release of lactate dehydrogenase from transfected cells.


CONCLUSIONS
This study demonstrates that restricted replication of enteroviral genomes in myocytes in a pattern similar to that observed in hearts with persistent viral infection can induce myocytopathic effects without generation of infectious virus progeny.
Department of Medicine, University of California, San Diego, School of Medicine, 92093-0613, USA.
R
R
Wessely
A
A
Henke
R
R
Zell
R
R
Kandolf
K U
KU
Knowlton
D000818:Animals; D000831:Animals, Newborn; D009202:Cardiomyopathies / Q000209:etiology / Q000235:genetics* / Q000821:virology; D002478:Cells, Cultured; D003384:Coxsackievirus Infections / Q000209:etiology / Q000235:genetics* / Q000821:virology; D003588:Cytopathogenic Effect, Viral / Q000235:genetics; D018076:DNA, Complementary / Q000235:genetics*; D004279:DNA, Viral / Q000235:genetics*; D029822:Enterovirus B, Human / Q000235:genetics* / Q000472:pathogenicity; D015967:Gene Expression Regulation, Viral / Q000235:genetics*; D005822:Genetic Vectors / Q000235:genetics; D006321:Heart / Q000821:virology*; D009154:Mutation / Q000235:genetics*; D009206:Myocardium / Q000166:cytology; D016133:Polymerase Chain Reaction / Q000379:methods; D012367:RNA, Viral / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley
D018076:DNA, Complementary; D004279:DNA, Viral; D012367:RNA, Viral